Clinical trial · Observational
Pleural Catheters Versus Thoracoscopic Pleurodesis
Comparative Effectiveness of Indwelling Pleural Catheters Versus Thoracoscopic Pleurodesis for Treatment of Malignant Pleural Effusions
NCT01117740CI-TRIAL-00021700completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical research study is to compare 2 different methods for treating a pleural effusion. Researchers also want to learn how the treatment you receive effects your quality of life (your ability to do the things you like to do and how happy you feel.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MDASI Questionnaire | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Thoracoscopy Group
- interventionNames
- Behavioral: MDASI Questionnaire
- label
- Indwelling Pleural Catheters
- interventionNames
- Behavioral: MDASI Questionnaire
Primary outcomes (1)
- measure
- Quality-Adjusted Survival Times
- timeFrame
- 12 Months with follow up until death or recurrence
- description
- Quality-adjusted time to death (measured as QALYs) for two patient groups (indwelling pleural catheters and thoracoscopy), calculated using Brazier's SF-6D utility measure described to determine utilities, then integrating utilities over time to arrive at quality-adjusted survival for each patient.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with MPE who are suitable for either pleural catheter placement or thoracoscopic pleurodesis who subsequently have either procedure performed 2. Sufficient mental capacity to answer SF-6D and Borg score questions 3. Age 18 or older 4. Life expectancy \> 2 months 5. English or Spanish speaking Exclusion Criteria: 1. Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax) 2. Inability or unwillingness to give informed consent 3. Inability to perform phone call follow-up 4. Pregnancy 5. Previous intrapleural therapy for MPE 6. Prior radiation therapy encompassing the entire hemithorax 7. Chylous effusions associated with malignant disease 8. Bilateral effusions requiring bilateral pleurodesis
References
Publications (1)
- DERIVEDOst DE, Jimenez CA, Lei X, Cantor SB, Grosu HB, Lazarus DR, Faiz SA, Bashoura L, Shannon VR, Balachandran D, Noor L, Hashmi YB, Casal RF, Morice RC, Eapen GA. Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters. Chest. 2014 Jun;145(6):1347-1356. doi: 10.1378/chest.13-1908. PMID 24480929